Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Consensus Target Price of $2.80 According to Brokerages

Aprea Therapeutics, Inc. (NASDAQ:APRE) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $2.80.

APRE has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Thursday, October 15th. LADENBURG THALM/SH SH began coverage on Aprea Therapeutics in a research note on Wednesday, October 14th. They issued a “buy” rating and a $2.00 price objective for the company. Finally, Wedbush decreased their target price on Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th.

Aprea Therapeutics Stock Up 4.5%

Shares of NASDAQ APRE opened at $0.52 on Friday. Aprea Therapeutics has a twelve month low of $0.41 and a twelve month high of $1.49. The stock’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.74. The company has a market capitalization of $7.34 million, a PE ratio of -0.74 and a beta of 1.74.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Wednesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, research analysts expect that Aprea Therapeutics will post -0.39 EPS for the current fiscal year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment.

The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer.